<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512316</url>
  </required_header>
  <id_info>
    <org_study_id>IMDCSACQEXT</org_study_id>
    <nct_id>NCT01512316</nct_id>
  </id_info>
  <brief_title>Exploring Learning and Unlearning of Fear</brief_title>
  <official_title>The Effect of D-cycloserine on Fear Learning and Extinction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study investigates the effect of d-cycloserine on learning and unlearning of fear
      in healthy humans and its underlying effect on the amygdala.

      As a second objective, the effect of genotype on fear learning will be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A growing body of evidence suggests that the extinction of fear is mediated by the
      N-methyl-D-aspartate (NMDA) receptor activity in the basolateral amygdala. Intra-amygdala
      infusions of antagonists of this glutamate receptor in small animals (eg: rats, mice) have
      demonstrated a blockage of fear acquisition and extinction. Agonists, on the other hand,
      facilitate conditioned fear extinction.

      The animal studies are all based on the simple fear learning paradigm of conditioning.
      However, it is not clear that human anxiety disorders are based on prior conditioning
      encounter. Therefore it is important to disentangle the effect of DCS on acquisition and
      extinction in the context of a simple learning paradigm, particular its effect on the human
      amygdala.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in BOLD-signal during a fear conditioning task</measure>
    <time_frame>t0, t+24, t+48</time_frame>
    <description>Subjects will participate in a 3-day experiment. Day1 (t0): Acquisition Day2 (T+24): extinction Day3 (T+48): re-exposure</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy Individuals</condition>
  <arm_group>
    <arm_group_label>d-Cycloserine Acquisition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>d-Cycloserine will be given on day1, before acquisition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>d-Cycloserine Extinction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>d-Cycloserine will be administered on day2, before extinction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo pill will be administered on day1 and 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-Cycloserine</intervention_name>
    <description>250mg, one dose, 2hrs prior to fMRI</description>
    <arm_group_label>d-Cycloserine Acquisition</arm_group_label>
    <arm_group_label>d-Cycloserine Extinction</arm_group_label>
    <other_name>Cycloserine, King Pharmaceuticals Ltd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose pill</intervention_name>
    <description>one dose, 2hrs prior to fmri</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Saliva sample</intervention_name>
    <description>Buccal cell material will be sampled from all participants on day3</description>
    <arm_group_label>d-Cycloserine Acquisition</arm_group_label>
    <arm_group_label>d-Cycloserine Extinction</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Whatman's Sterile Omni Swabs (www.whatman.com)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional neuroimaging (fMRI)</intervention_name>
    <arm_group_label>d-Cycloserine Acquisition</arm_group_label>
    <arm_group_label>d-Cycloserine Extinction</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No axis I diagnosis compatible with the DSM-IV by means of a structured diagnostic
             interview

          -  Right-handed

        Exclusion Criteria:

          -  Current psychopharmacological or psychological treatment.

          -  The presence of a physical/medical condition that may interfere with the study.

          -  A contraindication for the use of DCS

          -  Pacemaker, medication pump (such as insulin pump), hearing aid, removable
             prosthodontics

          -  Metal in or on body (such as acupuncture needles, artificial limbs, stents, metal
             splints, clips, implanted electrodes, tattoos, or piercings)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liesbet Goossens, PhD</last_name>
    <phone>+31 43 3685306</phone>
    <email>lies.goossens@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Sunaert, MD PhD</last_name>
    <phone>+32 16 349021</phone>
    <email>stefan.sunaert@uz.kuleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catholic University Leuven, Departement of Radiology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Sunaert, MD PhD</last_name>
      <phone>+32 16 349021</phone>
      <email>stefan.sunaert@uz.kuleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>January 13, 2012</last_update_submitted>
  <last_update_submitted_qc>January 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fear</keyword>
  <keyword>Cycloserine</keyword>
  <keyword>Conditioning</keyword>
  <keyword>Functional neuroimaging</keyword>
  <keyword>Anxiety disorders</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

